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Calcineurin inhibitor (CNI) toxicity contributes to chronic allograft nephropathy (CAN). In the 2-year, randomized, study, we
showed that 50% cyclosporin (CsA) reduction in combination with mycophenolate mofetil (MMF) treatment improves kidney
function without increasing the risk for graft rejection/loss. To investigate the long-term eﬀect of this regimen, we conducted
a follow up study in 70 kidney transplant patients until 5 years after REFERENCE initiation. The improvement of kidney
function was conﬁrmed in the MMF group but not in the control group (CsA group). Four graft losses occurred, 2 in each group
(graft survival in the MMF group 95.8% and 90.9% in control group). One death occurred in the control group. There was no
statistically signiﬁcant diﬀerence in the occurrence of serious adverse events or acute graft rejections. A limitation is the weak
proportion of patient still remaining within the control group. On the other hand, REFERENCE focuses on the CsA regimen
while opinions about the tacrolimus ones are still debated. In conclusion, CsA reduction in the presence of MMF treatment seems
to maintain kidney function and is well tolerated in the long term.
1.Introduction
Renal transplantations permit quality of life improvement
for patients presenting with chronic renal insuﬃciency, in
addition to increasing their life expectancy. Recent years
were marked by a reduction of acute rejection episodes and
improvedgraftsurvivalintheshorttermasaresultoftheuse
of calcineurin inhibitors (CNIs), without progress in long-
term graft survival [1]. This observation is attributable to the
nephrotoxic eﬀect of CNI [2], the long-term use of which
is implicated in the development of chronic allograft lesions
and suggested to contribute to chronic allograft nephropathy
(CAN).
It is thus considered primordial to avoid CNI toxicity
while at the same time minimizing the risk of renal dys-
function and graft loss. Consequently, a number of studies2 Journal of Transplantation
were conducted with reduction, withdrawal, or avoidance of
CNI, in particular of cyclosporin reviewed in [3, 4]. The ﬁrst
attempts of CNI withdrawal were associated with a signiﬁ-
cant increase in acute rejection incidents, thus rendering the
exact appraisal of the beneﬁt/risk ratio of such a regimen
diﬃcult[5–7].Theadventofnewimmunosuppressiveagents
suchasmycophenolatemofetil(MMF)revivedtheinterestin
alternative immunosuppressive treatment strategies.
MMF is the ester prodrug of mycophenolic acid (MPA),
which selectively and reversibly inhibits the rate-limiting
enzyme in the de novo biosynthesis of guanosine nucleotides
[8]. MMF reduces the risk of acute allograft rejection
incidents [9], without nephrotoxic side eﬀects [10], which is
suggestive of an ideal candidate for long-term CsA reduction
treatment strategies. Short-term studies have proven the
positive impact of CsA dose reduction with concomitant
MMFadministrationonrenalgraftfunction[11].Inarecent
publication concerning the DICAM study, a prospective
randomized trial conﬁrms these results [12]. However,
the study of long-term consequences of this approach is
important, given the possibility that the observed short-term
improvements might be the outcome of the elimination of
the functional CNI nephrotoxicity of vascular origin, and
thatlesionsinrelationtoreducedimmunosuppression could
eventually result in graft loss. Therefore, to address the
question whether renal function improvement in patients
with chronic allograft dysfunction observed in the initial
two-year REFERENCES study [13] would be maintained in
the long term, we conducted a follow up study for 5 years
after study initiation.
2.MaterialsandMethods
2.1. Study Design and Study Patients. The REFERENCE
study (Renal function evaluation after half dose reduction
of Neoral in combination with CellCept in renal transplant
patients with altered renal function) was an open, random-
ized,controlled,multicenter,prospectivestudy,conductedin
15centersinFrancebetweenMarch2000andFebruary2007.
The study was conducted in accordance with the Declaration
of Helsinki. All patients gave their written informed consent
beforeenteringthestudy,aftertheprotocolandtheinformed
consent form were approved by an Independent Ethics
Committee (IEC of Lorraine, France).
Initially, a study duration of 96 weeks was planned,
which was extended to ﬁve years with the approval of the
IEC. Study design and inclusion criteria for the initial study
were previously described in detail in [13]. Brieﬂy, eligible
patients were between 18–65 years old, had received a ﬁrst
or second renal graft from a deceased or living donor
one to ten years prior to the study, and were receiving a
CsA-based immunosuppressive treatment for at least three
months. Patients presented with CAD which was deﬁned by
alteredrenalfunctionasindicatedbyaserumcreatininelevel
between 1.7 and 3.4 mg/dL. Eligible patients were randomly
assigned to one of two treatment arms. Patients in the MMF
group received a dose of 2g MMF per day with half the
dose of CsA compared to the initial dose. Azathioprine
treatmentwastobestoppedbeforetheintroductionofMMF.
In the control group, patients received CsA according to the
center’s practice, with a minimal detectable target through
level of 100ng/mL. In both treatment arms corticosteroids
were prescribed following the practice of the center.
After completion of the initial study (96 weeks), patients
could choose to participate in the three-year follow up
phase, thus leading to a total study duration of ﬁve years.
Patients had to give their written informed consent for
study continuation. The details of the study design are
presented in Figure 1. The follow up phase required six
semiannual follow up visits which included a clinical and a
laboratory exam. The protocol did not deﬁne any treatment
for this period. Patients either continued with the treatment
they received during the initial study phase, or a change
of the immunosuppressor treatment was implemented at
the discretion of the investigator. The study populations
were thus deﬁned as follows. Randomization population:
MMF group–patients randomized to receive a 50% reduction
of CsA. Control group—patients randomized to receive
the usual CsA dose. On-treatment population: Group I—
patients who received a treatment with a mycophenolic acid
derivative(MMFormycophenolatesodium,MPS)attheend
of the follow up phase. Group II—patients without such a
treatment at the end of the follow up phase.
2.2. Primary and Secondary Endpoints. The study objective
was to determine if administration of MMF in combination
withCsAreductionby50%leadstoimprovementofallograft
function on the long term. The primary eﬃcacy endpoint
during the three-year follow up phase was the evolution of
allograft function as evaluated by 1/SeCr (inverse of serum
creatinine) between week 96 and the end of the three-year
follow up phase.
As secondary endpoints to assess allograft function
creatinine clearance (calculated with the Cockcroft’s for-
mula) and proteinuria were analyzed. Additional analyses
included graft and patient survival, occurrence of acute graft
rejection, recurrence of initial nephropathy, adverse events,
and laboratory parameters.
2.3. Statistical Analysis. No statistical hypothesis was for-
mulated for the three-year follow up phase. The analysis
populations were the randomization population and the on-
treatment population as described above. This comprised all
randomized patients who completed the initial study phase
and gave their consent to participate in the three-year follow
up. Results were expressed as mean ± standard deviation
(SD) for quantitative variables and absolute and relative
frequencies for qualitative variables. Continuous variables
were compared using analysis of variance while categorical
variables were analyzed with a chi-square test or the Fisher’s
exact test. Statistical analyses were performed with a two-
sided test with a signiﬁcance level of 5% using SAS software
(version 8.2, SAS Institute, Inc., Cary, NC, USA).
2.4. Role of Funding Source. The study sponsor, Roche
(Neuilly sur Seine, France), chose the participating centers,Journal of Transplantation 3
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Figure 1: Study design.
funded the creation of the centralized database and the
study monitoring, and employed an independent company
to conduct the statistical analysis and to participate in the
writing of the paper.
3. Results
3.1. Analysis Population. Among the 106 patients who were
enrolled in the initial study, 103 were randomized, 80
completedit,and71gavetheirinformedconsenttocontinue
in the three-year follow up phase (Figure 2). One of these
patients was excluded from the follow up phase due to
prematurewithdrawalfromtheinitialstudy.Baselinecharac-
teristics and demographics of patients included in the study
were previously described [13]. Among the 70 patients who
were included in the three-year follow up, 48 were part of the
MMF group, and 22 belonged to the control group. For anal-
ysis ﬁve years after study initiation patients were analyzed
according to whether or not they received a mycophenolic
acid derivative at the last visit. A total of 15 patients changed
treatment during the follow up phase. Three patients from
the MMF group stopped MMF treatment and were therefore
included in group II, while one patient switched from
MMF to MPS and was accounted for in group I. Eleven
patients from the control group were treated with MMF and
were therefore included in group I. Consequently, group I
consisted of 56 patients who were treated with MMF (55
patients) or MPS (1 patient) at the last visit or last available
visit for premature withdrawals, and group II included 14
patients who did not receive MMF or MPS treatment at the
end of the follow up phase. A total of eight patients (11.4%)
withdrew prematurely from the three-year follow up: ﬁve
patients in the MMF group and three patients in the control
group. See Table 1 and Figure 2 for details.
3.2. Immunosuppressive Treatment. During the follow up
phase patients either maintained or modiﬁed the immuno-
suppressive regimen they were assigned to in the initial study
phase.
Concerning MMF treatment (Table 2(a)) in the random-
ization population, the mean daily dose gradually decreased
from month 30 to month 60. This is mainly due to the
decrease of the proportion of patients taking exactly 2 g/day
in the MMF group from 75% to 60.5%. In the control group,
two patients (9%) received MMF at month 30 and nine
(47.4%) at month 60. Unlike previously, in the on-treatment
population the mean daily MMF dose and the proportion
of patients taking 2g/day increased in group I, from month
30 to month 60. In group II, there were still three patients
treated with MMF at month 48, but none thereafter.
Regarding CsA treatment (Table 2(b)), for the random-
ization population the mean daily CsA dose in the MMF
group remained stable from month 30 to month 60. At the
same time the mean daily CsA dose in the control group
progressively decreased. For the on-treatment population,
the mean daily CsA doses between month 30 and month 60
in group I were comparable to those in the MMF group. The
values in group II and control group were also comparable.
However, the values at month 48 in group II exceeded
200mg/day.
3.3. Renal Function. The evolution of renal function as
evaluated by the evolution of 1/SeCr in the randomization
population is shown in Figure 3(a).I nt h eM M Fg r o u p ,a
positive slope of this parameter was observed during the 24
months of the initial study phase. In the course of the follow
up phase, the 1/SeCr value, which was 0.49mg/dl ± 0.08
at baseline and 0.60mg/dl ± 0.13 at month 24, gradually
diminished to reach 0.55mg/dl ± 0.16 at month 60. It was
still signiﬁcantly higher compared to baseline (P = .018)
despite a reduction between month 24 and month 60. In
the control group, 1/SeCr values remained relatively stable
throughout the follow up phase, with 0.51mg/dl ± 0.08 at
baseline, 0.51mg/dl ± 0.10 at M24, and 0.49mg/dl ± 0.14
at M60. A transient increase was, however, noted at month
42 (0.53mg/dl ± 0.10), which was possibly inﬂuenced by
the withdrawal of two patients due to renal graft loss in this
group. No statistically signiﬁcant change was observed in the4 Journal of Transplantation
Table 1: Study withdrawal and reason for withdrawal.
Randomization population1 On-treatment population2 Total
MMF group3 (n = 48) Control group4 (n = 22) Group I5 (n = 56) Group II6 (n = 14) (n = 70)
Study withdrawal 5 (10.4%) 3 (13.6%) 7 (12.5%) 1 (7.1%) 8 (11.4%)
Graft loss 2 (4.2%) 2 (9.1%) 3 (5.4%) 1 (7.1%) 4 (5.7%)
P-value7 .585 1.000
Death 0 (0%) 1 (4.5%) 1 (4.5%) 0 (0%) 1 (1.4%)
Other8 3 (6.3%) 0 (0%) 3 (5.4%) 0 (0%) 3 (4.3%)
1 Patients randomized to receive either MMF or CsA treatment in the initial study phase.
2 Determined by the treatment patients received at the end of the post-trial phase (mycophenolic acid derivative or not).
3 Patients who received 2g MMF per day and 50% of the initial CsA dose.
4 Patients who received the usual CsA dose.
5 Patients who received a treatment with a mycophenolic acid derivative at the end of the follow up phase.
6 Patients without a mycophenolic acid derivative at the end of the follow up phase.
7 1 patient moved, 2 patients did not perform visit at month 60.
8 Comparison between groups of patients who had graft loss.
Table 2
(a) MMF treatment.
Randomization population1 On-treatment population2
MMF group3 Control group4 Group I5 Group II6
Patients
under
MMF
2g/day
Mean MMF
dose/day
Patients
under
MMF
treatment
Mean MMF
dose/day
Patients
under
MMF
2g/day
Mean MMF
dose/day
Patients
under
MMF
treatment
Mean MMF
dose/day
M30 36 (75.0%) 1844±295mg 2 (9.0%) 125 ± 448mg 36 (64.3%) 1549 ± 741mg 3 (21.4%) 321±668mg
M48 31 (70.5%) 1773±424mg 6 (33.4%) 500±786mg 33 (66.0%) 1650±600mg 3 (25.0%) 375±711mg
M60 26 (60.5%) 1628±608mg 9 (47.4%) 711±822mg 29 (59.2%) 1704±432mg 0 —
1 Patients randomized to receive either MMF or CsA treatment in the initial study phase.
2 Determined by the treatment patients received at the end of the post-trial phase (mycophenolic acid derivative or not).
3 Patients who received 2g MMF per day and 50% of the initial CsA dose.
4 Patients who received the usual CsA dose
5 Patients who received a treatment with a mycophenolic acid derivative at the end of the follow up phase.
6 Patients without a mycophenolic acid derivative at the end of the follow up phase.
(b) Mean CsA dose per day.
Randomization population1 On-treatment population2
MMF group3 Control group4 Group I5 Group II6
M30 129 ± 37mg 190 ± 50mg 137 ± 48mg 191 ± 30mg
M48 134 ± 47mg 180 ± 54mg 134 ± 41mg 205 ± 60mg
M60 126 ± 44mg 163 ± 43mg 128 ± 37mg 173 ± 63mg
1 Patients randomized to receive either MMF or CsA treatment in the initial study phase.
2 Determined by the treatment patients received at the end of the post-trial phase (mycophenolic acid derivative or not).
3 Patients who received 2 g MMF per day and 50% of the initial CsA dose.
4 Patients who received the usual CsA dose.
5 Patients who received a treatment with a mycophenolic acid derivative at the end of the follow up phase.
6 Patients without a mycophenolic acid derivative at the end of the follow up phase.
control group between baseline and month 60. 1/SeCr level
changes between baseline and month 60 were statistically
diﬀerent between the two groups (P = .025, 0.06mg/dl
± 0.15 in the MMF group and −0.03mg/dl ± 0.11 in the
control group), but no statistically signiﬁcant diﬀerence of
the 1/SeCr value at month 60 was observed between the
two groups (P = .134). The evolution of 1/SeCr in group
I of the on-treatment population was comparable to the
MMF group, resulting in a statistically signiﬁcant diﬀerence
between the two groups at month 60 (P = .024, Figure 3(b)).
In group I, 1/SeCr levels were signiﬁcantly higher at month
60 compared to baseline (P = .008). No such change wasJournal of Transplantation 5
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Figure 2: Study ﬂow chart.
observed in group II. The changes between baseline and
month 60 were statistically diﬀerent between the two groups
(P = .008, 0.05mg/dl ± 0.13 in group I and −0.06mg/dl ±
0.13 in group II).
Creatinine clearance as presented in Figure 4(a)
increased in the MMF group during the initial study period
(47.3mL/min ± 11.4 at baseline and 56.9mL/min ± 16.7 at
month 24) and gradually diminished during the post-trial
period to 51.8mL/min ± 20.2 at month 60. In the control
groupthisparameterremainedstableduringtheinitialstudy
phase (43.5mL/min ± 12.0 at baseline and 44.2mL/min ±
14.6atmonth24)andslightlydecreasedduringthepost-trial
phase to 41.3mL/min ± 18.9 at month 60. Analysis of group
I showed a result similar to the MMF group (Figure 4(b)),
while creatinine clearance in group II abruptly fell at month
54 and was 38.1mL/min ± 22.1 at month 60 compared to
45.8mL/min ± 16.4 at month 24. The diﬀerences observed
b e t w e e nM M Fa n dc o n t r o lg r o u pa n dg r o u pIa n dg r o u p
II at the end of the study were not statistically signiﬁcant
(P = .066). Creatinine clearance changes between baseline
and month 60 were not signiﬁcantly diﬀerent in any of the
four groups nor were the changes for the same time period
between the MMF group and the control group, and group I
and group II.
3.4. Secondary Endpoints
3.4.1.GraftandPatientSurvival. Asingle deathwasreported
during the three year follow up phase. This concerned a
patient from the control group who died from a metastatic6 Journal of Transplantation
non-small-cell lung cancer (Table 1). A total of four graft
losses occurred, two each in the MMF (graft survival 95.8%)
and in the CsA group (graft survival 90.9%) with no
statistically signiﬁcant diﬀerence between the two groups
(P = .585).
3.4.2. Renal Dysfunction. Renal dysfunction was deﬁned by
increased serum creatinine, acute graft rejection (biopsy
proven), chronic allograft nephropathy (biopsy proven), and
recurrence of the initial nephropathy. During the follow
up phase, 8 patients (16.7%) from the MMF group and 5
patients (22.7%) from the control group experienced at least
one renal dysfunction, with 10 patients (17.9%) in group I
and 3 patients (21.4%) in group II (Table 3). For the entire
duration of the study (5 years), the number of patients with
at least one episode of renal dysfunction was 8 in the MMF
group, 6 in the control group (27.3%), 10 in group I, and 4
in group II (28.6%).
3.4.3. Safety. Only serious adverse events (SAEs) were
r e c o r d e dd u ri n gt h i ss t u d y .At o t a lo f4 7ev e n t sw e r er e p o rt e d
for 29 patients in the follow up phase. This included 36 SAEs
observed in 21 patients (43.8%) of the MMF group and 11
SAEs in 8 patients (36.4%) of the control group. This corre-
sponds to 36 SAEs in 23 patients (41.1%) of group I, and 11
eventsinsixpatients(42.9%)ingroupII(Table 4).Nostatis-
tical signiﬁcant diﬀerence between the groups was observed.
Most frequently declared SAEs included infections and
infestations (11.4% of total patient population, 12.5% versus
9.1% in the MMF group and control group, resp.), cardiac
disorders (7.1% of total patient population, 8.3% versus
4.6% in the MMF group and control group, resp.), benign,
malignant, or unspeciﬁed tumors (7.1% of total patient
population,6.3%versus9.1%intheMMFgroupandcontrol
group, resp.), and surgical and medical interventions (5.7%
of total patient population, 8.3% versus 0% in the MMF
group and control group, resp.). Of note, no opportunistic
viral infection was reported, and gastrointestinal disorders
concerned only three patients.
3.4.4. Laboratory Values and Physical Exams. The evolution
of mean uremia, cholesterol, triglycerides, HDL cholesterol,
and proteinuria levels during the course of the study was
analyzed. No statistically or clinically signiﬁcant diﬀerence
was found between MMF versus control group and between
group I versus group II at month 60, nor between changes
between baseline and month 60 within the populations. Six
patients in the MMF group and one patient in the control
group had a proteinuria level superior to 3g/24h at one
or more assessment points during the three-year follow up
phase (data not shown). Finally, both mean systolic and
diastolic blood pressure (SBP, DBP) varied little during the
follow up phase in any of the groups analyzed.
4. Discussion
Despite the eﬃcacy of CsA in the prevention of acute graft
rejection and improvement of short-term graft survival,
CNI-associated nephrotoxicity remains a causal factor to
chronic allograft dysfunction and thus limits long-term
graft survival [14]. And histological markers of CsA-induced
nephrotoxicityasidentiﬁedbyrenalgraftbiopsiesareuniver-
sally present in renal allografts ten years after transplantation
[15].
The results of the present study concern only CsA.
While tacrolimus is also a CNI, his exact impact remains
still debated [16]. Some studies conﬁrm the positive
impact concerning tacrolimus treatment especially on renal
function. An association was demonstrated between the
tacrolimus dose and the renal function status. J. Pascual and
al. highlighted that everolimus with very low tacrolimus
regimen had clinically better renal function compared to
the low exposure tacrolimus arm [17]. Moreover, in the
SYMPHONY study, daclizumab, MMF, and corticosteroids
in combination with low-dose tacrolimus demonstrated a
better renal function, allograft survival, and acute rejection
rates as compared with regimens containing either low-
dose CsA or Sirolimus [18]. on the other hand, an increase
in interstitial ﬁbrosis and tubular atrophy (IF/TA) was
associated with a decrease in kidney function within patients
taking tacrolimus, MMF, and prednisone. Indeed, it has
repeatedly shown that IF/TA is associated with both allograft
dysfunction and allograft loss [19]. Moreover, other factors
couldalsobeimplicatedwithtacrolimusnephrotoxicitysuch
as the cytochrome genotype [20, 21]
Hence this demands alternative long-term immunosup-
pressive treatment options that reduce renal toxicity while
maintaining immunosuppression and preventing graft loss.
Complete CNI avoidance strategies proved mostly unsatis-
factory and resulted in increased acute rejection risk [22–
24]. CNI reduction or withdrawal regimens based on non-
nephrotoxic immunosuppressive agents such as MMF [25–
28] or sirolimus [29–31] yielded promising results regarding
improved renal function; however, some of these protocols
pose an increased risk for acute rejection, as demonstrated in
CsAwithdrawalunderMMFtreatmentindenovotransplant
patients [25, 26], as well as in late withdrawal in patients
with stable renal function [27, 28]. Furthermore, the use of
sirolimus is limited due to the high rate of adverse events
[32], and results that suggest improved renal function after
CsA withdrawal in sirolimus-treated patients [29, 30, 33]
may be confounded by an increased risk of toxicity resulting
from CsA and sirolimus coadministration in the control
groups. Another alternative has recently been introduced.
Indeed, Belatacept, a new immunosuppressive therapy,
allows avoiding the renal toxicities associated with CNI. Yet,
it is associated with a higher incidence and severity of acute
rejection episodes than with CsA regimen based [34].
The REFERENCE study was one of the ﬁrst randomized
and controlled studies to show that CsA reduction in
the presence of MMF improves renal function in renal
transplant recipients with impaired renal function [13]. Yet,
the question about long term risks and beneﬁts arising
from this treatment remained open. The goal of the present
three-year follow up phase was to evaluate the safety of the
treatment strategy and the maintenance of the therapeutic
response together with improved renal function.Journal of Transplantation 7
Table 3: Renal dysfunction.
Randomization population1 On-treatment population2 Total
MMF group3
(n = 48)
Control group4
(n = 22)
Group I5
(n = 56)
Group II6
(n = 14) (n = 70)
Number of events 12 6 15 3 18
Increased serum creatinine 7 (58.3%) 2 (33.3%) 8 (53.3%) 1 (33.3%) 9 (50%)
Acute rejection (biopsy proven) 0 (0%) 1 (16.7%) 1 (6.7%) 0 (0%) 1 (5.6%)
Chronic allograft nephropathy (biopsy proven) 3 (25%) 3 (50%) 4 (26.7%) 2 (66.7%) 6 (33.3%)
Recurrence of initial nephropathy 1 (8.3%) 0 (0%) 1 (6.7%) 0 (0%) 1 (5.6%)
Others 1 (8.3%) 0 (0%) 1 (6.7%) 0 (0%) 1 (5.6%)
Patients with at least one episode of renal
dysfunction 8 (16.7%) 5 (22.7%) 10 (17.9%) 3 (21.4%) 13 (18.6%)
1 Patients randomized to receive either MMF or CsA treatment in the initial study phase.
2 Determined by the treatment patients received at the end of the post-trial phase (mycophenolic acid derivative or not).
3 Patients who received 2g MMF per day and 50% of the initial CsA dose.
4 Patients who received the usual CsA dose.
5 Patients who received a treatment with a mycophenolic acid derivative at the end of the follow up phase.
6 Patients without a mycophenolic acid derivative at the end of the follow up phase.
Table 4: Serious Adverse Events (SAEs) during the three-year post-trial phase.
Randomization population1 On-treatment population2
MMF group3(N = 48) Control group4(N = 22) Group I5(N = 56) Group II6(N = 14) Total (N = 70)
nE nP nE nP nE nP nE nP nE nP
Total SAEs 36 11 36 11 47
Total patients with
at least one SAE
21
(43.8%)
8
(36.4%)
23
(41.1%)
6
(42.9%)
29
(41.4%)
P-value .560 .903
Infections∗ 8 6
(12.5%) 2 2
(9.1%) 8 6
(10.7%) 2 2
(14.3%) 10 8
(11.4%)
Cardiac disorders∗ 4 4
(8.3%) 1 1
(4.6%) 3 3
(5.4%) 2 2
(14.3%) 5 5
(7.1%)
Tumors∗ (benign,
malignant, not
speciﬁed)
3 3
(6.3%) 22 ( 9 . 1 % ) 4 4
(7.1%) 1 1
(7.1%) 5 5
(7.1%)
Surgical and
medical
interventions∗
4 4
(8.3%) —— 3 3
(5.4%) 1 1
(7.1%) 4 4
(5.7%)
Gastrointestinal
disorders∗ 2 2
(4.2%) 1 1
(4.6%) 2 2
(3.6%) 1 1
(7.1%) 3 3
(4.3%)
Urinary system
and kidney
disorders∗
2 2
(4.2%) 1 1
(4.6%) 3 3
(5.4%) —— 3 3
(4.3%)
Respiratory,
thoracic, and
mediastinal
disorders∗
3 3
(6.3%) —— 2 2
(3.6%) 1 1
(7.1%) 3 3
(4.3%)
1 Patients randomized to receive either MMF or CsA treatment in the initial study phase.
2 Determined by the treatment patients received at the end of the post-trial phase (mycophenolic acid derivative or not).
3 Patients who received 2g MMF per day and 50% of the initial CsA dose.
4 Patients who received the usual CsA dose.
5 Patients who received a treatment with a mycophenolic acid derivative at the end of the follow up phase.
6 Patients without a mycophenolic acid derivative at the end of the follow up phase.
Note:percentageswerecalculatedbasedonthenumberofpatientspergroup,nE:numberofevents,nP:numberofpatients. ∗ detailsofSAEspersystem/organ
were done for ones with an incidence ≥3%.8 Journal of Transplantation
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Figure 3: (a) Evolution of inverse of creatinine (1/SeCr) over time in the randomization population (MMF group versus control group).
(b) Evolution of inverse of creatinine (1/SeCr) over time in the on-treatment population (group I versus group II). The vertical, dotted line
separates initial study phase and follow up phase.
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Figure 4:(a).Evolutionofcreatinineclearanceovertimeintherandomizationpopulation(MMFgroupversuscontrolgroup).(b)Evolution
of creatinine clearance over time in the on-treatment population (group I versus group II). The vertical, dotted line separates initial study
phase and follow up phase.
Epidemiologic studies have shown that serum creatinine
and changes thereof are predictive for long-term graft
survival [35, 36]. Even in the light of conﬂicting data,
serum creatinine is thus considered as useful marker for
the survival of renal allografts [14, 37]. In the follow up
phase, when results were analyzed according to the initial
randomization groups, improvement of renal function as
conﬁrmedin theinitial studyphasebyapositive evolution of
1/SeCrandimprovedcreatinineclearanceintheMMFgroup
slowly tapered oﬀ during the post-trial phase. However,
1/SeCr levels at month 60 remained signiﬁcantly higher
compared to baseline in the MMF group. In addition,
patients in the on-treatment MMF group had statistically
signiﬁcantbetter1/SeCrlevelscomparedtotheon-treatmentJournal of Transplantation 9
CsA group at month 60. Furthermore, comparable results
were found in the MMF group and in the control group
regarding laboratory parameters, including proteinuria and
the incidence of SAEs in the course of the three-year
follow up phase. This indicates the absence of a detrimental
eﬀect of the regimen on the long term. The possibility
of an unfavorable long-term eﬀect was raised by the
observation that improvement of renal function occurred
relatively early during the initial study phase (16 weeks after
randomization). This eﬀe c tm i g h ts u g g e s th e m o d y n a m i c
mechanisms (loss of CsA-mediated vasoconstriction [38]) at
the origin of the observed improvement, and which might be
attenuated by long-term reduced immunosuppression. Such
an eﬀect is, however, refuted by the results of the follow up
phase.
Of further interest is the lack of any additional aggra-
vation in the CsA group in the course of the study, which
is in contrast to the ﬁndings by Dudley et al [39]. This
observation could be explained by the design of the present
study. After completion of the initial study phase, 50% of the
patients in the control group conversed to MMF treatment
andhadthereforetheirCsAdosereduced(thusthereduction
of the mean daily CsA dose during the follow up phase
in that group). The stabilization of renal damage in the
control group during the post-trial period might thus be
due to reduced CsA doses or MMF speciﬁc. Evidence from
animal models suggests that MMF may exert a positive eﬀect
on renal damage by antiﬁbrotic properties mediated by its
antiproliferative action on both immune and nonimmune
cells, including renal tubular cells and vascular smooth
muscle cells [8]. We sought to eliminate this protocol-related
bias by analyzing the perprotocol population, but in this case
the number of patients remaining in group II (14 patients)
was low for statistical analysis.
ApotentialriskofCNI-reducingregimensisanincreased
acute graft rejection rate, as observed in patients with stable
renal function [28]. Yet in our study, only a single case of
acute rejection was reported throughout the entire post-
trial phase, supporting the ﬁndings of previous studies in
renal function compromised patients [39, 40]. While the
absence of protocol biopsies is limiting the interpretation
of these results, it remains unlikely that a clinical graft
rejection, even if it was initially subclinical, would remain
undetected (e.g., no increase of serum creatinine), given the
duration of this study. Together with the results from the
initial study phase (no biopsy-proven acute rejection, graft
survival in the MMFgroup and control group 99% and 97%,
resp.), this suggests that the conversion period (4 weeks of
gradual CsA reduction) as well as the study design ensure an
adequate tolerance for the therapeutic strategy used. This is
corroborated by the low incidence of MMF adverse events,
especially of the more frequently reported ones, such as
digestive disorders [41].
CsA-reducing regimens were shown to reduce cardiovas-
cular risk factors including hypercholesterolemia and hyper-
tension [39, 40] and may therefore reduce cardiovascular
disorders which contribute to mortality and graft loss in
renal transplant patients [42–44]. In our study lipid proﬁle
and blood pressure were comparable in the MMF group
and in the control group, without any clinically signiﬁcant
incidents. Again, this result might be explained by the
reduced CsA dose patients received in the control group
during the three-year follow up phase.
Furthermore, recent studies demonstrated a statistically
signiﬁcant reduction of tumor rates in CsA-reduced regi-
mens. The only death that occurred during this study and
which was the consequence of a neoplastic complication
(lung carcinoma) concerned the control group.
The methodological limitations inherent to this type
of studies leave the comparison of the two study groups
diﬃcult, since a signiﬁcant number of patients from the
control group had their treatment changed to MMF.
Overall, the ﬁve-year REFERENCE study shows that
the regimen involving CNI reduction in combination with
MMFtreatmentprovidesafavorablebeneﬁt/riskratio.There
was no secondary aggravation related to immunological
phenomena, and improvement of allograft function as
analysed by 1/SeCr levels was sustained in the long term.
Importantly, this study ended on average 12-year post-
transplantation for the majority of patients. The published
half-life of renal allografts is ca. 8 years for deceased-donor
allografts and 12 years for living-donor allografts [45]. Our
ﬁndings suggest that the study regimen may retard allograft
deterioration.
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